Kymera Therapeutics, Inc.
KYMR
$30.02
$0.270.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.06% | -392.43% | -18.20% | -8.41% | -18.64% |
| Total Depreciation and Amortization | 40.18% | 123.01% | 122.01% | 115.33% | 66.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.29% | 9.38% | 8.08% | 5.71% | 71.50% |
| Change in Net Operating Assets | -332.63% | -129.86% | -109.82% | -84.44% | 47.27% |
| Cash from Operations | -99.92% | -867.98% | -58.59% | -21.78% | 9.95% |
| Capital Expenditure | 93.69% | 91.95% | 102.34% | 56.45% | -84.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 115.19% | 127.31% | -330.17% | -56.38% | -1,230.36% |
| Cash from Investing | 114.70% | 261.80% | -360.58% | -56.35% | -1,444.81% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 4.48% | -131.68% | -88.53% | -5.39% | 11.31% |
| Issuance of Common Stock | -99.85% | 3,014.07% | 187,630.60% | 7.63% | 23,725.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.93% | 42.97% | 121,904.85% | 8.20% | 30,422.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.14% | -66.99% | 50.21% | -1,470.87% | 9.78% |